反応式
[Cl:1][C:2]1[CH:3]=[C:4]([CH:17]=[CH:18][C:19]=1[Cl:20])[CH2:5][NH:6][C:7]([NH:9][C:10]1[S:11][CH:12]=[C:13]([CH:15]=O)[N:14]=1)=[O:8].[OH-].[Na+].[NH2:23][CH2:24][CH2:25][CH2:26][P:27](=[O:30])([OH:29])[OH:28].C([BH3-])#N.[Na+]>CO.[Br-].C([N+](CCCC)(CCCC)CCCC)CCC>[Cl:1][C:2]1[CH:3]=[C:4]([CH:17]=[CH:18][C:19]=1[Cl:20])[CH2:5][NH:6][C:7](=[O:8])[NH:9][C:10]1[S:11][CH:12]=[C:13]([CH2:15][NH:23][CH2:24][CH2:25][CH2:26][P:27](=[O:28])([OH:30])[OH:29])[N:14]=1参加物
7
実験手順
300 mg of 1-(3,4-dichlorobenzyl)-3-(4-formylthiazol-2-yl) urea was dissolved in 5 ml MeOH. 1.0 eq. of tetrabutylammonium bromide and 1.0 eq. of sodium hydroxide were added followed by addition of 1.0 eq. of 3-aminopropylphosphonic acid. To the mixture, 3.0 eq. of sodium cyanoborohydride was added and the reaction was stirred at room temp. overnight. The reaction mixture was loaded to reverse phase column and purified by HPLC to give 3-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methylamino)propylphosphonic acid.
後処理
- custompurified by HPLC
出典と根拠
- ORDレコード
- ord-34b40dc733d64cd18ec8505e2014876e
- 出典データセット
- uspto-grants-2012_04
- 特許番号
- US08148380B2
関連ノート
読み込み中…